TG Therapeutics, Inc.

TGTX · Nasdaq · ·

Comparar

US$ 64,49-0,1%fechamento 13 de nov.

Números até 30 de setembro de 2026, do 10-Q arquivado em 9 de novembro de 2026

1W: +7,8%
1M: +18,6%

Just reported

Q3 2026 results

From TG Therapeutics's results release of 9 de novembro de 2026; its quarterly report has since been filed.

Revenue
Actual
US$ 259,9M
+61% y/y
+8,2% q/q
Guided
—
No guide given
EPS, GAAP
Actual
US$ 0,35
-86% y/y
Guided
—
No guide given
Operating income, GAAP
Actual
US$ 85,9M
+193% y/y
+296% q/q
Guided
—
No guide given

Company outlook

Full year 2026

RevenueUS$ 1B+62% y/y Raised +5,3%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes TG Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

Highest-graded in Biotechnology

Graded A or B and worth $2B or more: A first, then the largest.

All 355 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Demonstrações financeiras completas →

Construído a partir dos próprios documentos de TG Therapeutics, Inc. entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.

TG Therapeutics, Inc.

TG Therapeutics, Inc.

Q3 2026 results

Revenue

EPS, GAAP